Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Short Interest Rises in Trump Media Stock After $6 Billion Merger Announcement 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing 
NextEra Energy Stock Rises After Reaffirming Earnings and Dividend Growth Outlook 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
Trump Blocks HieFo’s Emcore Chip Assets Deal Over National Security Concerns 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Grok AI Faces Global Scrutiny Over Safeguard Failures and Illegal Content on X 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
NEW YORK, March 13, 2017 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Stemline Therapeutics, Inc. securities (NASDAQ:STML): (1) pursuant and/or traceable to Stemline’s secondary public offering on or about January 20, 2017; and/or (2) publicly traded on the open market between January 19, 2017 and February 1, 2017, both dates inclusive (the “Class Period”) of the important April 4, 2017 lead plaintiff deadline in the class action filed by the Rosen Law Firm. The lawsuit seeks to recover damages for Stemline investors under the federal securities laws.
To join the Stemline class action, go to http://www.rosenlegal.com/cases-1048.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) a cancer patient in a Stemline clinical trial tied to SL-401 died from a severe side effect on January 18, 2017; and (2) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 4, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1048.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
